¼¼°èÀÇ CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, Á¡À¯À², ¿¹Ãø(2025-2032³â)
CRISPR and Cas Gene Market, By Product, By Application, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1663515
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 303 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,535,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,488,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,884,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

CRISPR/Cas À¯ÀüÀÚ ½ÃÀå ±Ô¸ð´Â 2024³â 48¾ï 9,943¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025-2032³â°£16.90%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

CRISPR/Cas À¯ÀüÀÚ ½ÃÀå ¿ªÇÐ

ÀÇ·á ¹× ³ó¾÷ ºÐ¾ß¿¡¼­ Á¤¹ÐÇÑ À¯ÀüÀÚ ÆíÁý µµ±¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

CRISPR/Cas ½Ã½ºÅÛ°ú °°Àº Á¤¹Ð À¯ÀüÀÚ ÆíÁý µµ±¸¿¡ ´ëÇÑ ¼ö¿ä´Â ÀÇ·á ¹× ³ó¾÷ ºÐ¾ß¿¡¼­ Çõ½Å °¡´É¼º°ú ºñ¿ë È¿À²¼ºÀ¸·Î ÀÎÇØ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ºÐ¾ß¿¡¼­ CRISPRÀº Áúº´À» À¯¹ßÇÏ´Â µ¹¿¬º¯À̸¦ Á÷Á¢ ±³Á¤ÇÔÀ¸·Î½á À¯ÀüÀÚ Áúȯ¿¡ ´ëÇÑ È¹±âÀûÀÎ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, °â»ó ÀûÇ÷±¸ ºóÇ÷°ú º£Å¸ ÁöÁßÇØ ºóÇ÷ Ä¡·á¿¡¼­ À¯¸ÁÇÑ °á°ú¸¦ º¸¿©ÁÖ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÀÌ ±â¼úÀº À¯ÀüÀÚ Á¶ÀÛ T¼¼Æ÷°¡ ƯÁ¤ Á¾¾ç ¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î »ï´Â ¾Ï ¸é¿ª Ä¡·á¿¡µµ ¸Å¿ì Áß¿äÇϸç, °³ÀÎ ¸ÂÃãÇü ÀǷḦ ¹ßÀü½Ãų ¼ö ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¼ö¹é¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â À¯Àü¼º Áúȯ Áõ°¡´Â Ä¡·á ¿¬±¸¿¡ CRISPR ±â¼úÀ» äÅÃÇÏ´Â Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, ¾à 1¸¸¿© Á¾ÀÇ ´Ü¹ß¼º ÁúȯÀÌ À¯ÀüÀÚ ÆíÁýÀÇ ¹ßÀüÀ¸·Î Ä¡·áµÉ °¡´É¼ºÀÌ ÀÖ´Ù°í ÇÕ´Ï´Ù. ³ó¾÷ ºÐ¾ß¿¡¼­ CRISPRÀº ÀÛ¹° °øÇÐÀ» ÀçÁ¤ÀÇÇÏ°í °úÇÐÀÚµéÀÌ ÇØÃæ ÀúÇ×¼º, °¡¹³ ÀúÇ×¼º, ¿µ¾ç °­È­ ÀÛ¹°À» °³¹ßÇÏ¿© ½Ä·® ºÒ¾È¿¡ ´ëóÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¶ÇÇÑ, È­ÇÐ ³ó¾à°ú È­ÇÐ ºñ·á¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÁÙÀÓÀ¸·Î½á Áö¼Ó °¡´ÉÇÑ ³ó¾÷À» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ³ó¹«ºÎ(USDA)´Â 2023³â À¯ÀüÀÚ ÆíÁý ÀÛ¹°ÀÌ ÇâÈÄ 10³â°£ ½Ä·® »ý»êÀ» ÃÖ´ë 30%±îÁö ²ø¾î¿Ã¸± ¼ö ÀÖ´Ù°í º¸°íÇϸç, ÀÌ ±â¼úÀÌ ¼¼°è ³ó¾÷ ¹®Á¦¸¦ ÇØ°áÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ» °­Á¶Çß½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¾ß¿¡¼­ CRISPRÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ZFNÀ̳ª TALEN°ú °°Àº ±âÁ¸ ±â¼ú¿¡ ºñÇØ Á¤¹Ð¼º, È¿À²¼º, °æÁ¦¼ºÀÌ ¶Ù¾î³ª±â ¶§¹®À̸ç, ÀÇ·á¿Í ½Ä·® »ý»ê ¸ðµÎ¿¡¼­ °ÔÀÓ Ã¼ÀÎÀú°¡ µÇ°í ÀÖ½À´Ï´Ù.

CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : ÁÖ¿ä °íÂû

CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

¼¼°è CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀº Á¦Ç°, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªÀ» ±âÁØÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç°¿¡ µû¶ó CRISPR Á¦Ç°°ú CRISPR ¼­ºñ½ºÀÇ µÎ °¡Áö ¹üÁÖ·Î ³ª´µ´Âµ¥, CRISPR Á¦Ç°Àº À¯ÀüÀÚ ÆíÁý, ¿¬±¸ ¹× Ä¡·á °³¹ß ºÐ¾ß¿¡¼­ ³Î¸® ÀÀ¿ëµÇ°í ÀÖÀ¸¸ç, ŸÀÇ ÃßÁ¾À» ºÒÇãÇÏ´Â Á¤È®¼º°ú È¿À²¼ºÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. »ç¿ëÀÚ Ä£È­ÀûÀΠŰƮ, ½Ã¾à, °í±Þ Cas ´Ü¹éÁúÀÇ °¡¿ë¼ºÀ¸·Î ÀÎÇØ ÀÇ·á, ³ó¾÷, »ý¸í°øÇÐ »ê¾÷ Àü¹Ý¿¡ °ÉÃÄ ±Þ¼ÓÇÑ º¸±ÞÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚ¿¡ µû¶ó Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷, ÇÐ°è ¹× ¿¬±¸±â°ü, CROÀÇ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷µéÀº ½Å¾à°³¹ß, À¯ÀüÀÚ Áúȯ Ä¡·á, °³ÀÎ ¸ÂÃãÇü ÀÇ·á °³¹ßÀ» À§ÇÑ À¯ÀüÀÚ ÆíÁý ±â¼ú¿¡ ´ë±Ô¸ð ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. À̵éÀÇ ÅºÅºÇÑ ¿¬±¸ ÀÎÇÁ¶ó¿Í ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ÁýÁßÀº Çõ½ÅÀûÀÎ CRISPR ±â¹Ý ¼Ö·ç¼ÇÀÇ »ó¿ëÈ­¸¦ °¡¼ÓÈ­ÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : Áö¿ªº° ºÐ¼®

CRISPR/Cas À¯ÀüÀÚ ½ÃÀåÀº ±â¼ú ¹ßÀü, ¿¬±¸ ÀÚ±Ý, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ½ÃÀå µµÀÔÀÇ Â÷ÀÌ·Î ÀÎÇØ Áö¿ªº°·Î ¶Ñ·ÇÇÑ Â÷À̸¦ º¸À̰í ÀÖ½À´Ï´Ù. ºÏ¹Ì°¡ ¼¼°è ½ÃÀåÀ» ¼±µµÇϰí ÀÖ´Â °ÍÀº À¯ÀüÀÚ ÆíÁý ±â¼ú¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ, źźÇÑ »ý¸í°øÇÐ »ê¾÷, Á¤ºÎÀÇ Áö¿ø Á¤Ã¥¿¡ ±âÀÎÇÕ´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº ÁÖ¿ä Á¦¾àȸ»ç¿Í ¿¬±¸±â°ü °£ÀÇ ±¤¹üÀ§ÇÑ Á¶»ç ÀÌ´Ï¼ÅÆ¼ºê¿Í °øµ¿¿¬±¸°¡ ÀÌ·ç¾îÁö°í ÀÖ¾î ¿ìÀ§¸¦ Á¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)¿¡ µû¸£¸é, ¹Ì±¹ Á¤ºÎ´Â ÃÖ±Ù CRISPR °ü·Ã ¿¬±¸ ÇÁ·ÎÁ§Æ®¿¡ 10¾ï ´Þ·¯ ÀÌ»óÀÇ ÀÚ±ÝÀ» ¹èÁ¤Çß½À´Ï´Ù. À¯·´Àº °­·ÂÇÑ Çмú ¿¬±¸ ÀÎÇÁ¶ó¿Í Ä¡·á ÀÀ¿ë ºÐ¾ß¿¡¼­ CRISPR ±â¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå Á¡À¯À²ÀÌ µÎµå·¯Áö°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º¿Í °°Àº ±¹°¡µéÀº ƯÈ÷ ³ó¾÷ »ý¸í°øÇÐ ¹× Á¤¹ÐÀÇ·á ºÐ¾ß¿¡¼­ CRISPR Çõ½ÅÀÇ ÃÖÀü¼±¿¡ ¼­ ÀÖ½À´Ï´Ù. ±×·¯³ª À¯ÀüÀÚ º¯Çü¿¡ ´ëÇÑ ±ÔÁ¦Àû Á¦¾àÀº ¿©ÀüÈ÷ °úÁ¦·Î ³²¾Æ ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÁÖ·Î Áß±¹, ÀϺ», Çѱ¹ µîÀÇ ±¹°¡µéÀÇ »ý¸í°øÇÐ »ê¾÷ È®Àå¿¡ ÈûÀÔ¾î ºü¸¥ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Áß±¹Àº ƯÈ÷ ³ó¾÷ ¹× Áúº´ Ä¡·á ºÐ¾ß¿¡¼­ À¯ÀüÀÚ ÆíÁý ¿¬±¸¿Í ÀÓ»ó Àû¿ë¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇϸ鼭 ÁÖ¿ä ±â¾÷·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â ½Ä·® ¾Èº¸¿Í °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¼ö¿ä°¡ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½ÅÈï ½ÃÀå¿¡¼­´Â ³ó¾÷ÀÇ ¹ßÀü°ú ÀÇ·áÀÇ Çö´ëÈ­¸¦ ¹è°æÀ¸·Î CRISPR ±â¼úÀÇ Ã¤ÅÃÀÌ Á¡Â÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : °æÀï ±¸µµ

CRISPR/Cas À¯ÀüÀÚ ½ÃÀåÀº °æÀïÀÌ Ä¡¿­Çϸç, ±âÁ¸ ±â¾÷¿Í ½Å»ý ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷ÀÌ È¥ÀçµÇ¾î ´Ù¾çÇÑ ¿ëµµ·Î Çõ½ÅÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¾÷üµéÀº Á¦¾à, »ý¸í°øÇÐ, ³ó¾÷ ºÐ¾ß ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ À¯ÀüÀÚ ÆíÁý ŰƮ, ½Ã¾à, CRISPR °ü·Ã ¼­ºñ½º µî CRISPR ±â¹Ý ÷´Ü Á¦Ç° °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº CRISPR ±â¼úÀÇ Á¤È®¼º, È¿À²¼º, È®À强À» ³ôÀ̱â À§ÇÑ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ÀÌ´Â »ó¾÷È­ ¼º°ø¿¡ ÇʼöÀûÀÔ´Ï´Ù. °æÀï ȯ°æÀº Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í ½ÃÀå µµ´Þ ¹üÀ§¸¦ È®´ëÇϱâ À§ÇÑ Àü·«Àû ÆÄÆ®³Ê½Ê, Á¦ÈÞ, Àμö¸¦ ÅëÇØ Ư¡Áö¾îÁý´Ï´Ù. ÁÖ¿ä ¾÷üµéÀº ¶ÇÇÑ »õ·Î¿î À¯ÀüÀÚ ÆíÁý µµ±¸ ¹× Ä¡·á¹ý °³¹ßÀ» °¡¼ÓÈ­Çϱâ À§ÇØ ÇÐ°è ¹× ¿¬±¸ ±â°ü°ú Çù·ÂÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾÷üµéÀº °æÀï ¿ìÀ§¸¦ È®º¸Çϱâ À§ÇØ »ê¾÷ »ý¸í°øÇÐ ¹× ȯ°æ ÀÀ¿ë ºÐ¾ß¿Í °°Àº ÀüÅëÀûÀÎ ÀÇ·á ¹× ³ó¾÷ ÀÌ¿ÜÀÇ ¿ëµµ¸¦ ¸ð»öÇÏ¿© Á¦Ç°À» ´Ù¾çÈ­Çϰí ÀÖÀ¸¸ç, CRISPR ±â¹Ý Ä¡·áÁ¦ ¹× ³ó»ê¹°¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀÌ ÁøÇàµÊ¿¡ µû¶ó ½ÃÀå °ü°èÀÚµéÀº ½ÅÈï ½ÃÀå¿¡¼­ Àå±âÀûÀÎ ¼ºÀåÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. Àå±âÀûÀÎ ¼ºÀåÀ» ¸ñÇ¥·Î Çϰí ÀÖÀ¸¸ç, ´Ù¾çÇÑ ±ÔÁ¦ ȯ°æÀ» ±Øº¹Çϱâ À§ÇÑ ±âȸ¿Í µµÀüÀÌ ¸ðµÎ Á¸ÀçÇÕ´Ï´Ù. Àü¹ÝÀûÀ¸·Î ±â¼ú ¹ßÀü, Çõ½Å, Àü·«Àû »ç¾÷ È®ÀåÀ» ÅëÇØ °æÀïÀÌ Ä¡¿­ÇØÁö°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå CRISPR/Cas À¯ÀüÀÚ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå ±¸µµ

Á¦7Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : Á¦Ç°º°

Á¦8Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : ¿ëµµº°

Á¦9Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : CRISPR/Cas À¯ÀüÀÚ ¾÷°è

Á¦12Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

CRISPR and Cas Gene Market size was valued at US$ 4,899.43 Million in 2024, expanding at a CAGR of 16.90% from 2025 to 2032.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas (CRISPR-associated) Genes form a groundbreaking gene-editing technology that allows precise alterations in DNA sequences. CRISPR acts as a natural immune defense mechanism in bacteria, while Cas proteins (such as Cas9) serve as molecular scissors guided by RNA to cut specific DNA strands. This system's ability to edit genes with unmatched accuracy has revolutionized genetic research and therapeutic development. The need for CRISPR-Cas technology stems from its potential to address genetic disorders by directly modifying faulty genes. Unlike traditional gene therapies, CRISPR is faster, cost-effective, and more precise, making it a superior choice for treating inherited diseases. It plays a pivotal role in personalized medicine, where tailored genetic interventions offer targeted treatment. Moreover, in agriculture, CRISPR enhances crop yields, pest resistance, and nutritional content, improving global food security. CRISPR's importance lies in its vast applications across healthcare, agriculture, and scientific research. It offers hope for curing genetic diseases like cystic fibrosis and sickle cell anemia, drives innovation in cancer immunotherapy, and aids in developing new antiviral treatments. Additionally, it empowers fundamental biological research by enabling detailed studies of gene functions. CRISPR-Cas technology continues to reshape science, holding transformative potential for human health and sustainability.

CRISPR and Cas Gene Market- Market Dynamics

Rising demand for precise gene-editing tools in healthcare and agriculture

The demand for precise gene-editing tools like CRISPR-Cas systems is surging in healthcare and agriculture due to their transformative potential and cost-effectiveness. In healthcare, CRISPR enables groundbreaking therapies for genetic disorders by directly correcting disease-causing mutations. For instance, it has shown promising results in treating sickle cell anemia and beta-thalassemia. Additionally, the technology is pivotal in cancer immunotherapy, where engineered T cells target specific tumor cells, advancing personalized medicine. The global rise in genetic disorders, affecting millions, is a key driver for adopting CRISPR technology in therapeutic research. According to the World Health Organization (WHO), approximately 10,000 monogenic diseases can potentially be treated through gene-editing advancements. In agriculture, CRISPR is redefining crop engineering, allowing scientists to develop pest-resistant, drought-tolerant, and nutritionally enhanced crops to combat food insecurity. It supports sustainable farming by reducing dependence on chemical pesticides and fertilizers. The U.S. Department of Agriculture (USDA) reported in 2023 that gene-edited crops could boost food production by up to 30% over the next decade, emphasizing the technology's potential to address global agricultural challenges. The rising adoption of CRISPR across these sectors is driven by its precision, efficiency, and affordability compared to older techniques like ZFNs and TALENs, making it a game-changer in both medicine and food production.

CRISPR and Cas Gene Market- Key Insights

CRISPR and Cas Gene Market- Segmentation Analysis:

The Global CRISPR and Cas Gene Market is segmented on the basis of Product, Application, End-User, and Region.

The market is divided into two categories based on Product: CRISPR Products, and CRISPR Services. CRISPR Products dominate the market due to their widespread application in gene editing, research, and therapeutic development, offering unmatched precision and efficiency. The availability of user-friendly kits, reagents, and advanced Cas proteins has driven rapid adoption across healthcare, agriculture, and biotechnology industries.

The market is divided into three categories based on End-User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, and Contract Research Organizations. Pharmaceutical and Biotechnology Companies dominate the market due to their extensive investments in gene-editing technologies for drug discovery, genetic disease therapies, and personalized medicine development. Their robust research infrastructure and focus on clinical trials accelerate the commercialization of innovative CRISPR-based solutions, driving market growth.

CRISPR and Cas Gene Market- Geographical Insights:

The CRISPR and Cas gene market exhibits significant regional variations driven by differences in technological advancements, research funding, regulatory frameworks, and market adoption. North America leads the global market, attributed to substantial investments in gene-editing technologies, a robust biotechnology industry, and supportive government policies. The United States, in particular, dominates due to extensive research initiatives and collaborations between leading pharmaceutical companies and research institutions. According to the National Institutes of Health (NIH), the U.S. government allocated over $1 billion in funding for CRISPR-related research projects in recent years. Europe holds a prominent market share, driven by strong academic research infrastructure and rising adoption of CRISPR technologies in therapeutic applications. Countries like Germany, the United Kingdom, and France are at the forefront of CRISPR innovations, particularly in agricultural biotechnology and precision medicine. However, regulatory constraints around genetic modifications remain a challenge. Asia-Pacific is experiencing rapid growth, primarily fueled by expanding biotechnology industries in countries like China, Japan, and South Korea. China has emerged as a major player, with aggressive investments in gene-editing research and clinical applications, especially in agriculture and disease treatment. The region's rising focus on food security and personalized medicine further accelerates demand. Emerging markets in Latin America and the Middle East & Africa are gradually adopting CRISPR technologies, driven by agricultural advancements and healthcare modernization.

CRISPR and Cas Gene Market- Competitive Landscape:

The CRISPR and Cas gene market is highly competitive, with a mix of established players and emerging biotech firms driving innovation across various applications. Companies in the market are focusing on developing advanced CRISPR-based products, such as gene-editing kits, reagents, and CRISPR-related services, to cater to the increasing demand from the pharmaceutical, biotechnology, and agricultural sectors. These companies invest heavily in research and development to enhance the precision, efficiency, and scalability of CRISPR technology, which is vital for successful commercialization. The competitive landscape is characterized by strategic partnerships, collaborations, and acquisitions aimed at expanding product portfolios and market reach. Key players are also engaging in alliances with academic institutions and research organizations to accelerate the development of new gene-editing tools and therapies. In addition, companies are diversifying their offerings by exploring applications beyond traditional healthcare and agriculture, such as industrial biotechnology and environmental applications, to gain a competitive edge. With growing regulatory approval for CRISPR-based therapies and agriculture products, market players are positioning themselves for long-term growth in emerging markets, which presents both opportunities and challenges in navigating diverse regulatory environments. Overall, the competition is intense, driven by technological advancements, innovation, and strategic business expansion.

Recent Developments:

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CRISPR AND CAS GENE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL CRISPR AND CAS GENE MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

GLOBAL CRISPR AND CAS GENE MARKET, BY APPLICATION - MARKET ANALYSIS, 2019 - 2032

GLOBAL CRISPR AND CAS GENE MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL CRISPR AND CAS GENE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. CRISPR and Cas Gene Market Overview

2. Executive Summary

3. CRISPR and Cas Gene Key Market Trends

4. CRISPR and Cas Gene Industry Study

5. CRISPR and Cas Gene Market: Impact of Escalating Geopolitical Tensions

6. CRISPR and Cas Gene Market Landscape

7. CRISPR and Cas Gene Market - By Product

8. CRISPR and Cas Gene Market - By Application

9. CRISPR and Cas Gene Market - By End-User

10. CRISPR and Cas Gene Market- By Geography

11. Key Vendor Analysis- CRISPR and Cas Gene Industry

12. 360 Degree AnalystView

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â